File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: The Task-force in Europe for Drug Development for the Young (TEDDY) network of excellence

TitleThe Task-force in Europe for Drug Development for the Young (TEDDY) network of excellence
Authors
KeywordsChildren
Legislation
Pharmacology
Research and development
Issue Date2009
PublisherAdis International Ltd. The Journal's web site is located at http://pediatrics.adisonline.com/
Citation
Pediatric Drugs, 2009, v. 11 n. 1, p. 18-21 How to Cite?
AbstractThe Task-force in Europe for Drug Development for the Young (TEDDY) was established in 2005 to contribute to the promotion of safe and efficacious medicines for children in the context of the impending European Paediatric Regulation that finally came into force in January 2007. The project includes seven objectives and 12 Work-Packages encompassing the main aspects of the development and use of pediatric drugs. TEDDY represents a new entity in the pediatric pharmaceutical field, differing from a Scientific Society, a network for developing research or trials, or a consultative regulatory body. The ambition of TEDDY is to support the existing pediatric networks, societies, and regulatory bodies in performing innovative initiatives, including those in areas in which such undertakings would not be feasible without supportive action. To accomplish its aim, TEDDY has focused on three different actions: (i) increasing awareness about the Paediatric Regulation revolution; (ii) reaching consensus on terms and instruments to be used for common research; and (iii) favoring close relationships among different stakeholders and partners from different EU Member States. After 3 years of activities, many results have been produced by the Network: surveys, databases, expert opinions, and recommendations. Linking together different stakeholders, including industry and patient associations, as well as academia and research centers, the Network has contributed to increasing awareness and participation in the Paediatric Regulation. In addition, many papers detailing original results have either been published or submitted for publication in peer-reviewed journals. TEDDY is an original Network whose identity and role as a catalyzer of initiatives related to the use and development of pediatric drugs needs to be better clarified in the near future. Of particular importance is the need to reach consensus on best practices. The lack of a common view on pediatric research requirements among stakeholders across Member States remains the main challenge to be overcome. © 2009 Adis Data Information BV. All rights reserved.
Persistent Identifierhttp://hdl.handle.net/10722/132901
ISSN
2023 Impact Factor: 3.4
2023 SCImago Journal Rankings: 1.017
References

 

DC FieldValueLanguage
dc.contributor.authorCeci, Aen_HK
dc.contributor.authorGiaquinto, Cen_HK
dc.contributor.authorAboulker, JPen_HK
dc.contributor.authorBaiardi, Pen_HK
dc.contributor.authorBonifazi, Fen_HK
dc.contributor.authorDella Pasqua, Oen_HK
dc.contributor.authorNicolosi, Aen_HK
dc.contributor.authorTaruscio, Den_HK
dc.contributor.authorSturkenboom, Men_HK
dc.contributor.authorWong, Ien_HK
dc.date.accessioned2011-04-04T07:57:53Z-
dc.date.available2011-04-04T07:57:53Z-
dc.date.issued2009en_HK
dc.identifier.citationPediatric Drugs, 2009, v. 11 n. 1, p. 18-21en_HK
dc.identifier.issn1174-5878en_HK
dc.identifier.urihttp://hdl.handle.net/10722/132901-
dc.description.abstractThe Task-force in Europe for Drug Development for the Young (TEDDY) was established in 2005 to contribute to the promotion of safe and efficacious medicines for children in the context of the impending European Paediatric Regulation that finally came into force in January 2007. The project includes seven objectives and 12 Work-Packages encompassing the main aspects of the development and use of pediatric drugs. TEDDY represents a new entity in the pediatric pharmaceutical field, differing from a Scientific Society, a network for developing research or trials, or a consultative regulatory body. The ambition of TEDDY is to support the existing pediatric networks, societies, and regulatory bodies in performing innovative initiatives, including those in areas in which such undertakings would not be feasible without supportive action. To accomplish its aim, TEDDY has focused on three different actions: (i) increasing awareness about the Paediatric Regulation revolution; (ii) reaching consensus on terms and instruments to be used for common research; and (iii) favoring close relationships among different stakeholders and partners from different EU Member States. After 3 years of activities, many results have been produced by the Network: surveys, databases, expert opinions, and recommendations. Linking together different stakeholders, including industry and patient associations, as well as academia and research centers, the Network has contributed to increasing awareness and participation in the Paediatric Regulation. In addition, many papers detailing original results have either been published or submitted for publication in peer-reviewed journals. TEDDY is an original Network whose identity and role as a catalyzer of initiatives related to the use and development of pediatric drugs needs to be better clarified in the near future. Of particular importance is the need to reach consensus on best practices. The lack of a common view on pediatric research requirements among stakeholders across Member States remains the main challenge to be overcome. © 2009 Adis Data Information BV. All rights reserved.en_HK
dc.languageengen_US
dc.publisherAdis International Ltd. The Journal's web site is located at http://pediatrics.adisonline.com/en_HK
dc.relation.ispartofPediatric Drugsen_HK
dc.subjectChildrenen_HK
dc.subjectLegislationen_HK
dc.subjectPharmacologyen_HK
dc.subjectResearch and developmenten_HK
dc.titleThe Task-force in Europe for Drug Development for the Young (TEDDY) network of excellenceen_HK
dc.typeArticleen_HK
dc.identifier.emailWong, I: wongick@hku.hken_HK
dc.identifier.authorityWong, I=rp01480en_HK
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.2165/0148581-200911010-00008en_HK
dc.identifier.pmid19127946-
dc.identifier.scopuseid_2-s2.0-58149359052en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-58149359052&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume11en_HK
dc.identifier.issue1en_HK
dc.identifier.spage18en_HK
dc.identifier.epage21en_HK
dc.publisher.placeNew Zealanden_HK
dc.identifier.scopusauthoridCeci, A=7006836326en_HK
dc.identifier.scopusauthoridGiaquinto, C=7006585659en_HK
dc.identifier.scopusauthoridAboulker, JP=7004644119en_HK
dc.identifier.scopusauthoridBaiardi, P=6603678168en_HK
dc.identifier.scopusauthoridBonifazi, F=15047380400en_HK
dc.identifier.scopusauthoridDella Pasqua, O=8536932300en_HK
dc.identifier.scopusauthoridNicolosi, A=7006060070en_HK
dc.identifier.scopusauthoridTaruscio, D=7003387113en_HK
dc.identifier.scopusauthoridSturkenboom, M=21743803900en_HK
dc.identifier.scopusauthoridWong, I=7102513915en_HK
dc.identifier.issnl1174-5878-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats